All molecular sub-types are found in ER+ve breast cancers
ER+ve cancers have better short-term prognosis but kill more women than ER-ve cases
HIGH ER risk of late relapse & Death in ER+ve vs ER-ve BCs
Relapse risks persist for at least 20 years in ER+ve BCA
The persistent challenge of ER+ve early breast cancers
- ER+ve breast cancers represent the largest proportion of newly diagnosed breast cancers
- Mortality from ER+ve/HER2-ve breast cancer is proportionally lower but numerically higher during the first 5 years post diagnosis.
- After 5 years patients with ER+ve breast cancer are at higher risk of metastasis than patients with ER-ve disease
- Improvements in outcome, based on novel therapeutic approaches, have been less impactful for ER+ve/HER-ve cancers than for other subgroups.
This event is sponsored by: :